Garcinone B

Garcinone B: A Comprehensive Reference

1. Identity and Chemical Characterization

Nomenclature and Registry

Garcinone B is a naturally occurring polyphenolic compound belonging to the xanthone class of secondary metabolites. Its molecular formula is C₂₃H₂₂O₆, and it is registered in the PubChem database under Compound ID (CID) 5495928. Its CAS registry number is 76996-28-6. Garcinone B is a derivative of γ-mangostin, placing it within the prenylated xanthone subclass.

Structural Class: Xanthones

Xanthone (9H-xanthene-9-one) is a unique chemical structure with a dibenzo-γ-pyrone heterocyclic scaffold. Lichens, fungi, plants from the Polygalaceae, Moraceae, Gentianaceae, and Guttiferae families, and ferns all contain these tricyclic secondary chemicals, and because of their chemical makeup and the position of substituent groups on the aromatic ring, they exhibit a variety of biological actions. Garcinone B was described as one of three new tetraoxygenated xanthones — garcinones A, B, and C — each disubstituted with C5-units, isolated from the chloroform extract of the fruit-hulls of Garcinia mangostana, with structures established by a combination of spectral interpretation and chemical correlation.

Natural Sources

Garcinone B has been identified in two distinct natural botanical contexts. Its primary documented plant source is Garcinia mangostana L. (commonly known as mangosteen), a tropical tree of the family Clusiaceae (formerly Guttiferae). Garcinia mangostana Linn. belongs to the family Guttiferae and is named "the queen of fruits," cultivated in the tropical rainforest of Southeast Asian nations including Indonesia, Malaysia, Sri Lanka, the Philippines, and Thailand. Xanthones have been isolated from the pericarp, whole fruit, heartwood, and leaves of this plant; the most studied xanthones in this species are α-, β-, and γ-mangostins, garcinone E, 8-deoxygartanin, and gartanin.

A second documented botanical source is Hypericum patulum Thunb. (family Hypericaceae), specifically from its callus tissue cultures. A study reported garcinone B — along with a new xanthone named paxanthone B and 1,3,6,7-tetrahydroxy-8-(3-methyl-2-butenyl)-9H-xanthen-9-one — as known compounds isolated from callus tissues of Hypericum patulum, with structures elucidated using spectral techniques. The 2005 pharmacological study by Yamakuni et al. further confirmed garcinone B as "a xanthone from callus tissue culture of Hypericum patulum."

Isolation and Common Forms

In research settings, garcinone B is typically isolated by solvent extraction followed by chromatographic separation. It has been isolated from the chloroform extract of the fruit-hulls of Garcinia mangostana. The pericarp of Garcinia mangostana is a source of xanthones and other bioactive substances; prenylated xanthones isolated from this plant have been extensively studied, with some members possessing antioxidant, antitumoral, antiallergic, anti-inflammatory, antibacterial, antifungal, and antiviral properties. In commerce and research, garcinone B is primarily available as a purified reference standard. It does not appear in significant concentrations as a named ingredient in formulated dietary supplements; rather, it is present as one constituent among many xanthones in mangosteen pericarp extracts and preparations.

---

2. Traditional and Historical Use

Garcinone B itself has no documented history of deliberate traditional use as a named compound — it was only structurally characterized in the modern era. Its traditional use context is therefore inseparable from that of its parent plant, Garcinia mangostana.

Southeast Asian Traditional Medicine

Garcinia mangostana is cultivated in the tropical rainforest of Southeast Asian nations including Indonesia, Malaysia, Sri Lanka, the Philippines, and Thailand, where people have used the pericarp (peel, rind, hull, or ripe) as a traditional medicine for the treatment of abdominal pain, diarrhea, dysentery, infected wound, suppuration, and chronic ulcer. The pericarp of its fruit has been used extensively in Southeast Asia for centuries to treat skin infections, wounds, and other medical conditions.

The pericarp of Garcinia mangostana has also been used in traditional folk medicine to treat gonorrhea, bladder infections, and skin rash for hundreds of years in Southeast Asia. Traditional medicine preparations using the mangosteen pericarp include treatments for inflammation, infections, wounds, and diarrhea.

Ayurvedic Tradition

In the Ayurvedic system of medicine, the fruit hull of Garcinia mangostana finds wide application, mainly as an anti-inflammatory agent and in the treatment of diarrhoea. In Ayurveda, both the pericarp (rind) and the aril are used: the pericarp in powdered or decocted form for digestive unrest; the aril fresh or dried as a cooling tonic.

Preparation Methods

Traditional preparations of mangosteen pericarp in Southeast Asia and South Asia encompass decoctions, infusions, and dried powders. The seeds and pericarps of the fruit have a long history of use in the traditional medicinal practices of the region, and beverages containing mangosteen pulp and pericarps are sold worldwide as nutritional supplements. In contemporary contexts, since its introduction into the United States, juices and products containing mangosteen fruit have become a top-selling botanical dietary supplement.

Hypericum patulum, the second identified botanical source of garcinone B, has its own ethnobotanical history in East Asia, including traditional uses in countries such as Japan and China. However, specific traditional preparations attributed to garcinone B from H. patulum are not documented in the available peer-reviewed literature reviewed here.

---

3. Chemistry: Key Constituents and Structural Features

Xanthone Scaffold and Substitution Pattern

Chemically, xanthones (9H-xanthen-9-ones) encompass a family of compounds with an oxygen-containing dibenzo-γ-pyrone heterocyclic scaffold and provide a wide range of different substitutions modulating several biological responses, thus being considered a promising and interesting structure for drug development. Xanthones are secondary metabolites found in plants, fungi, lichens, and bacteria from a variety of families and genera, with the majority found in the Gentianaceae, Polygalaceae, and Clusiaceae; they have a diverse range of bioactivities, including antioxidant, antibacterial, antimalarial, antituberculosis, and cytotoxic properties.

Garcinone B is a tetraoxygenated, prenylated xanthone. Structural features that may confer interesting biological activities on xanthones include prenylation, the presence of hydroxyl groups at specific ring positions, and the attachment of furan rings to the xanthone C-ring. The structure of a xanthone determines its bioactivity, and different substitutions can result in variable bioactivity.

Relationship to Other Garcinia Xanthones

Within the xanthone family of Garcinia mangostana, garcinone B is one of several named garcinone analogs. The pericarp of Garcinia mangostana is a source of xanthones and other bioactive substances, and prenylated xanthones isolated from it have been extensively studied, with some members possessing antioxidant, antitumoral, antiallergic, anti-inflammatory, antibacterial, antifungal, and antiviral properties. Xanthones, a unique scaffold with a 9H-xanthen-9-one core structure, widely exist in natural sources; over 250 xanthones have been isolated and identified in plants from the families Gentianaceae and Hypericaceae alone.

---

4. Mechanisms of Action

Inhibition of Cyclooxygenase Enzymes (COX-1 and COX-2)

The most thoroughly investigated mechanism of garcinone B is its ability to interfere with the prostaglandin biosynthesis pathway. Garcinone B — a derivative of γ-mangostin — potently inhibits COX-1 and COX-2 activities to reduce prostaglandin E2 (PGE2) release from C6 rat glioma cells, and inhibits IKK activity to prevent NF-κB-dependent COX-2 gene transcription. This dual mechanism — enzyme inhibition and transcriptional suppression — distinguishes garcinone B from classical non-steroidal anti-inflammatory drugs (NSAIDs), which typically act primarily at the enzyme level rather than at the gene regulatory level.

Inhibition of the NF-κB Signaling Pathway

Garcinone B also prevented LPS-induced stimulation of NF-κB-dependent transcription. Nuclear factor kappa-B (NF-κB) is a central transcription factor in the regulation of inflammatory gene expression, including COX-2. By inhibiting IκB kinase (IKK) — the upstream kinase that activates NF-κB — garcinone B interferes with the induction of COX-2 at the gene level, supplementing its direct enzyme inhibitory activity. These results suggest that garcinone B becomes a unique pharmacological tool to investigate intracellular signaling pathways involved in inflammation.

Reduction of Prostaglandin E2 (PGE2)

Garcinone B, to a lesser extent than γ-mangostin and the structurally related compound patulone, reduced A23187-induced increase in prostaglandin E2 release in C6 rat glioma cells. The A23187 calcium ionophore model is used experimentally to stimulate arachidonic acid release and subsequent eicosanoid production, meaning that garcinone B's PGE2-lowering effect occurs at or upstream of arachidonic acid mobilization, as well as at the COX enzyme level.

Anti-Tuberculosis Mechanism

Garcinone B has been reported to inhibit Mycobacterium tuberculosis with a minimum inhibitory concentration (MIC) of 12.7 µg/mL. The precise mechanistic basis for this antitubercular activity has not been fully elucidated in the available literature, but it is consistent with antimycobacterial properties reported for multiple prenylated xanthones from Garcinia species.

Class-Level Mechanisms: Xanthone Scaffold Biology

Naturally occurring xanthones have been discussed in the scientific literature for their notable biological activities, including antifungal, antibacterial, anticancer, coagulant, antioxidant, anti-inflammatory, and anti-HIV/AIDS activities. The xanthone scaffold's polyphenolic hydroxyl groups are central to its antioxidant and enzyme-inhibitory activities, while prenyl side chains influence membrane permeability and bioavailability. The polyphenolic xanthone entity is distinguished by its capacity to modulate inflammation, notably via the inhibition of the COX-2 enzyme and associated inflammatory pathways.

---

5. Scientific Evidence by Area of Use

5.1 Anti-Inflammatory Activity

Available evidence: Preclinical (in vitro), single cell-based study.

The most specific published study on garcinone B as an isolated compound is a 2006 pharmacological investigation by Yamakuni et al. (published in Neuroscience Letters, PMID 16260090). This study identified garcinone B as a compound that potently inhibits COX-1 and COX-2 activities to reduce PGE2 release from C6 rat glioma cells, and inhibits IKK activity to prevent NF-κB-dependent COX-2 gene transcription. Garcinone B, to a lesser extent than γ-mangostin and patulone, reduced A23187-induced increase in PGE2 release in C6 cells, and also prevented LPS-induced stimulation of NF-κB-dependent transcription.

This study was conducted entirely in a rat glioma cell line (C6 cells) — an in vitro model. No animal (in vivo) studies and no human clinical studies are available for garcinone B's anti-inflammatory properties as an isolated compound. The anti-inflammatory evidence for the broader class of Garcinia mangostana xanthones is more extensive but concerns different individual compounds (primarily α-mangostin, γ-mangostin, and garcinone E). The evidence for garcinone B specifically must therefore be characterized as preliminary and preclinical only.

5.2 Antibacterial Activity, Including Anti-Tuberculosis

Available evidence: Preclinical (in vitro MIC data).

α-Mangostin and β-mangostin inhibited Mycobacterium tuberculosis (MIC: 6.2 µg/mL), as did garcinone B (MIC: 12.7 µg/mL), according to a study by Suksamrarn et al. (2003). This MIC value indicates moderate antitubercular activity in vitro. No in vivo animal models or human clinical trials have tested garcinone B against tuberculosis or other bacterial infections as an isolated compound.

The broader context of antimicrobial activity of Garcinia xanthones is noted in the scientific literature. Experimental studies have demonstrated that extracts of Garcinia mangostana have antioxidant, antitumoral, antiallergic, anti-inflammatory, antibacterial, and antiviral activities. However, these broad-spectrum activities are attributed to the mixture of xanthones and other constituents in the extract and cannot be assigned specifically to garcinone B without targeted isolation studies.

5.3 Potential Cytotoxic / Anticancer Activity (Context)

Available evidence: Class-level in vitro data; garcinone B-specific evidence absent.

No published studies examining the cytotoxic or anticancer activity of garcinone B as an isolated compound against cancer cell lines were identified in the peer-reviewed literature reviewed for this article. However, the closely related garcinone analogs have been studied: garcinone E efficiently reduced the clonogenic capacity of HeLa cells; its anti-viability action was determined to be apoptosis-allied (supported by western blotting); cell cycle arrest occurred at the G2/M phase; and HeLa cell migration and invasion were reduced efficiently after garcinone E treatment in a dose-dependent fashion, indicating remarkable potential as an anti-cervical cancer chemopreventive agent.

Experimental studies have demonstrated that extracts of Garcinia mangostana have antitumoral activities; the pericarp is a source of xanthones; and prenylated xanthones isolated from it have been extensively studied, with some members possessing antitumoral properties. These class-level observations should not be extrapolated to attribute specific anticancer activity to garcinone B without compound-specific evidence.

5.4 Antioxidant Activity (Context)

Available evidence: Class-level; garcinone B-specific evidence absent from primary literature reviewed.

Mangosteen has been shown to exhibit numerous biological and pharmacological activities, including antioxidant properties. The antioxidant capacity of Garcinia mangostana extracts and individual xanthones has been investigated in many studies, but direct DPPH or ORAC assays specifically using isolated garcinone B were not identified in the literature reviewed. Prenylated xanthones isolated from Garcinia mangostana have been extensively studied, with some members possessing antioxidant properties. Whether garcinone B shares significant antioxidant activity comparable to α-mangostin or other well-studied analogs requires dedicated investigation.

5.5 Neurological / Glioma Cell Context

Available evidence: In vitro in rat glioma cells only.

The key pharmacological study on garcinone B used C6 rat glioma cells as the model system. While this demonstrates activity in neural tissue-derived cells, it should not be interpreted as evidence for clinical neurological benefit. The C6 glioma cell model is commonly used to study inflammatory signaling in the central nervous system context, and the study's finding that garcinone B becomes a unique pharmacological tool to investigate intracellular signaling pathways involved in inflammation reflects its value as a research reagent rather than as an established therapeutic agent.

---

6. Body Systems and Health Areas of Association

• Inflammatory pathways: Garcinone B inhibits COX-1 and COX-2 activities to reduce PGE2 release and inhibits IKK activity to prevent NF-κB-dependent COX-2 gene transcription — placing it in the category of compounds with mechanistic relevance to acute and chronic inflammatory conditions.
• Immune and innate defense signaling: Its inhibition of NF-κB, preventing LPS-induced stimulation of NF-κB-dependent transcription, positions it as a modulator of innate immune gene regulation pathways.
• Antimicrobial defense (preclinical): Garcinone B inhibited Mycobacterium tuberculosis in vitro at an MIC of 12.7 µg/mL.
• Digestive system (via parent plant tradition): The pericarp of Garcinia mangostana has been used traditionally for treatment of abdominal pain, diarrhea, dysentery, infected wound, suppuration, and chronic ulcer, though these uses relate to the whole pericarp, not to garcinone B specifically.

---

7. Dosage Forms and Dosages Reported in Studies

No human clinical dosage data for garcinone B exists in the peer-reviewed literature reviewed for this article, as no clinical trials involving garcinone B as an isolated compound have been published. Garcinone B is not marketed as a stand-alone dietary supplement ingredient with defined dosing.

In the preclinical research setting, garcinone B is studied as a purified compound. The key published study (Yamakuni et al., 2006, Neuroscience Letters) reported in vitro experiments in C6 rat glioma cells, but specific concentration ranges used in that cell-based assay are available only in the full text of the paper, which is behind a paywall and not directly quotable here.

The only quantitative dosage data verifiable from reviewed sources for garcinone B relates to its antitubercular in vitro activity: Garcinone B was reported to inhibit M. tuberculosis at an MIC of 12.7 µg/mL. This figure represents a minimum inhibitory concentration in a microbiological assay and does not translate directly to any human dose.

Mangosteen pericarp extract products (which contain garcinone B as one of many constituents) are commercially sold in various forms — juices, capsules, powders — but these products are standardized, if at all, to total xanthone content (most commonly α-mangostin), not to garcinone B specifically. In the US, mangosteen juice is among the best-selling herbs and botanicals. The proportion of garcinone B in such preparations has not been established in the sources reviewed.

---

8. Safety Considerations and Interactions

Garcinone B–Specific Safety Data

No published human safety data, toxicity studies, or adverse event reports specifically attributable to garcinone B as an isolated compound are available in the peer-reviewed literature reviewed for this article. Garcinone B has not been the subject of formal toxicological evaluation (NOAEL, LOAEL, LD50 determination) in any published animal or human study identified here. The compound is used primarily as a research tool and is not established as a dietary supplement ingredient at defined doses.

Class-Level Safety Context: Mangosteen Xanthones

Safety information about the broader category of mangosteen-derived xanthones, in which garcinone B is included, provides limited relevant context. A large variety of biological activities of xanthones have been reported, including cytotoxicity on cancer cells; the seeds and pericarps of the mangosteen fruit have a long history of use in the traditional medicinal practices of the region; the main phytochemicals present are isoprenylated xanthones, a class of secondary metabolites with multiple reports of biological effects including antioxidant, pro-apoptotic, anti-proliferative, antinociceptive, anti-inflammatory, neuroprotective, hypoglycemic, and anti-obesity activities.

Drug Interaction Context: P-Glycoprotein Modulation

A recognized concern for the xanthone class as a whole is modulation of drug transport proteins. Xanthones have been studied as P-glycoprotein modulators with an impact on drug bioavailability. P-glycoprotein (P-gp) is a major efflux transporter expressed in the intestine, liver, kidney, and blood–brain barrier, influencing the absorption and distribution of many pharmaceutical drugs. Whether garcinone B specifically modulates P-gp has not been established in studies reviewed here, but this is a class-level concern relevant to any xanthone consumed alongside pharmaceutical agents.

Limitations of the Safety Assessment

The absence of published safety data for garcinone B as an isolated compound means that no meaningful safety profile can be constructed specific to this compound. Any discussion of safety necessarily draws on data from structurally related mangosteen xanthones, whole-fruit extract studies, or class-level pharmacological considerations. The compound's activity against COX-1 — Garcinone B potently inhibits COX-1 and COX-2 activities — raises the theoretical concern, common to all COX-1–inhibiting agents, of potential effects on platelet aggregation and gastric mucosal integrity, though this has not been tested in any published in vivo or clinical study specifically for garcinone B.

---

9. Research Status and Evidence Summary

Garcinone B occupies an early-stage position in pharmacological research. Its discovery as a named compound in Garcinia mangostana fruit-hulls dates to the early 1980s, with structural identification published in Phytochemistry (21: 1747–1750, 1982). Its pharmacological characterization as an anti-inflammatory agent via COX and NF-κB inhibition was established in a 2006 in vitro study. Its antitubercular MIC was reported in a Suksamrarn et al. (2003) study on Garcinia xanthones.

No human clinical trials, no systematic reviews, and no meta-analyses involving garcinone B as an isolated, defined intervention have been published. All pharmacological evidence is at the in vitro or in vitro microbiological level. Garcinone B is not recognized by major regulatory bodies (FDA, EMA, EFSA) as an approved drug or supplement ingredient, and it does not appear in WHO monographs, ESCOP monographs, the German Commission E monographs, or the USP as a stand-alone ingredient. Its significance in current science is as a research tool and a constituent of the well-studied mangosteen xanthone family, rather than as an established therapeutic agent.

Till now, over 250 xanthones have been isolated and identified in plants from the families Gentianaceae and Hypericaceae, and many xanthones have been found to have anti-inflammatory properties in different models, either in vitro or in vivo — a broader context that situates garcinone B within a large and actively investigated chemical class. Naturally occurring xanthones have been documented for notable biological activities including antifungal, antibacterial, anticancer, antioxidant, and anti-inflammatory activities, but the translation of these class-level activities to garcinone B specifically requires targeted, compound-level investigation that has not yet been conducted at clinical scale.

References

• Yamakuni T et al. "Garcinone B reduces prostaglandin E2 release and NF-κB-mediated transcription in C6 rat glioma cells." Neuroscience Letters, 2006. ScienceDirect.
• PubChem. "Garcinone B | C23H22O6 | CID 5495928." National Library of Medicine / NIH.
• Sen AK et al. "The structures of garcinones A, B and C: Three new xanthones from Garcinia mangostana." Phytochemistry, 1982. ScienceDirect.
• Pedraza-Chaverri J et al. "Medicinal properties of mangosteen (Garcinia mangostana)." Food and Chemical Toxicology, 2008. PubMed.
• Cuesta-Rubio O et al. "Prenylated Benzophenones and Xanthones from Hypericum scabrum." ResearchGate.
• Bruneton J et al. "Antibacterial phenolic compounds from the flowering plants of Asia and the Pacific." Pharmaceutical Biology, 2024. Taylor & Francis.
• Guo J et al. "Garcixanthones B and C, new xanthones from the pericarps of Garcinia mangostana and their cytotoxic activity." ScienceDirect.
• Ahmad B et al. "Garcinone-E exhibits anticancer effects in HeLa human cervical carcinoma cells." PMC / NIH, 2020.
• Asase A et al. "Naturally Occurring Xanthones and Their Biological Implications." PMC / NIH, 2024.
• Guo LL et al. "Xanthones, A Promising Anti-Inflammatory Scaffold: Structure, Activity, and Drug Likeness Analysis." PMC / NIH, 2020.
• Wang X et al. "Xanthone Glucosides: Isolation, Bioactivity and Synthesis." PMC / NIH, 2021.
• Obolskiy D et al. "Medicinal properties of mangosteen (Garcinia mangostana L.): A comprehensive update." Food and Chemical Toxicology, 2017. ScienceDirect.
• Teh SS et al. "LC-QTOF-MS analysis of xanthone content in different parts of Garcinia mangostana and its influence on cholinesterase inhibition." PMC / NIH, 2020.
• ClinicalTrials.gov. "Bioavailability of Xanthones From Mangosteen." NCT01425047.
• Cheng L et al. "Cytotoxic Isopentenyl Phloroglucinol Compounds from Garcinia xanthochymus." PMC / NIH, 2023.